Lite Strategy (LITS) investor relations material

Executive summary

• Transitioned from oncology drug development to a dual focus on pre-clinical nononcology R&D and a digital asset treasury strategy centered on Litecoin (LTC) holdings.

• Advanced active treasury management by generating $0.7 million in net proceeds from a covered call options program on LTC holdings since October 2025.

• Repurchased 1,629,136 shares using both covered call proceeds and 35,250 LTC, reflecting disciplined capital allocation.

• Implemented a $25M share repurchase program, funded by proceeds from covered call options on LTC and digital asset sales.

• Closed a $100M PIPE financing, issuing common stock and pre-funded warrants, and entered new asset management and advisory agreements.

Financial highlights

• Reported a net loss of $23.7M for the quarter and $58.1M for the nine months ended March 31, 2026, compared to net losses of $2.6M and $13.3M in the prior year periods.

• Operating expenses rose sharply to $21.6M for the quarter, driven by a $18.8M loss in fair value of digital assets.

• Cash and cash equivalents were $7.5M, with $40.3M in unrestricted digital assets as of March 31, 2026.

• $94.8M in net cash provided by financing activities, primarily from PIPE and ATM equity offerings.

• $0.7 million in net proceeds generated from covered call options on LTC holdings since October 2025.

Outlook and guidance

• Sufficient liquidity to fund operations for at least 12 months, with flexibility to liquidate digital assets if needed.

• Ongoing pre-clinical R&D in nononcology indications and continued digital asset treasury operations.

• Plans to scale the covered call options program and continue executing a $25 million share repurchase authorization.

• Actively evaluating strategic investments and partnerships to drive LTC acceptance and ecosystem growth.